Kidney Sodium Functional Imaging

Sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Study ID
NCT05014178
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Sodium-23 MRI — DIAGNOSTIC_TEST
    Participants will lay in the MRI bed for approximately 60 minutes during scanning while the MRI technologist takes detailed pictures of their kidneys.

Study Details

The corticomedullary gradient is largely responsible for developing the gradients that are needed to concentrate urine (more solutes and less water). The ability of the kidneys to produce concentrated urine is a major determinant of the ability to survive the warm weather. When temperatures are high, we lose water through sweat, and so the kidneys retain water to maintain fluidity in the blood. The maintenance of a sodium (salt) gradient is required for urine concentration because increased medullary sodium concentration increases the reabsorption of water into the kidney, to be redistributed in the blood. The purpose of this study is to know if the corticomedullary gradient is altered in patients across a wide spectrum of kidney disease using sodium Magnetic Resonance Imaging (MRI), a machine that takes pictures and measures the salt content in the kidneys. 23Na kidney MRI, will provide functional MR of the kidney as a non-invasive tool to describe medullary function to improve management of chronic and kidney disease.

Key Dates

Start date
Sep 16, 2021
Status verified
Feb 2025
Primary completion
Dec 31, 2025
Completion
Feb 28, 2026

Study Design

Enrollment
200 participants (estimated)

Arms

  • Arm: Adult CKD stage 1-5 participants
    * Age greater than or equal to 18 years * Estimated GFR \< 90 mL/min/1.73m²
  • Arm: Adult transplanted participants
    • Age greater than or equal to 18 years
  • Arm: Adult dialysis participants
    * Age greater than or equal to 18 years * More than 3 months duration of therapy
  • Arm: Adult ADPKD
    • Age greater than or equal to 18 years
  • Arm: Adults treated for nephrolithiasis
    • Age greater than or equal to 18 years
  • Arm: Adult healthy controls including kidney donors
    * Age greater than or equal to 18 years * Lack of kidney disease, heart failure, liver cirrhosis and peripheral

Primary Outcome Measure

Exploratory cortico-medullary gradient measurement [ Time Frame: Throughout study visit, on average 2 hours ]

Central Contacts

Related Studies